Carcinoma in situ of skin of lower limb, including hip
ICD-10 D04.7 is a billable code used to indicate a diagnosis of carcinoma in situ of skin of lower limb, including hip.
Carcinoma in situ (CIS) of the skin is a non-invasive form of skin cancer characterized by the presence of abnormal cells that have not yet invaded deeper tissues. Specifically, D04.7 refers to CIS located on the lower limb, including the hip. This condition is often identified through skin examinations and biopsies, where atypical keratinocytes are found confined to the epidermis. Risk factors for developing CIS include prolonged sun exposure, fair skin, and a history of skin lesions. Patients may present with various skin changes, including scaly patches, non-healing sores, or changes in existing moles. Early detection and treatment are crucial to prevent progression to invasive carcinoma. Treatment options typically include surgical excision, cryotherapy, or topical chemotherapy. Regular surveillance is essential for patients diagnosed with CIS, as there is a risk of progression to invasive cancer if left untreated. The prognosis is generally favorable with appropriate management.
Detailed descriptions of lesions, biopsy results, and treatment plans.
Diagnosis and management of skin lesions, follow-up for CIS, and treatment of skin cancers.
Ensure accurate documentation of lesion characteristics and treatment response.
Comprehensive treatment history, including surgical and non-surgical interventions.
Management of skin cancer patients, including surveillance and treatment of CIS.
Focus on the risk of progression and the need for ongoing monitoring.
Used when excising a CIS lesion from the lower limb.
Document the size, location, and pathology results of the excised lesion.
Dermatologists should ensure accurate coding based on the excised lesion's characteristics.
Carcinoma in situ is a critical early stage of cancer where abnormal cells are present but have not invaded surrounding tissues. Early detection and treatment are essential to prevent progression to invasive cancer.
